

IN THE CLAIMS

Please cancel claims 3, 4, 5, 10, 11 and 12 without prejudice or disclaimer.

Please amend claims 1, 8 and 9 as follows below. In accordance with 37 C.F.R. § 1.21(c)(1), a marked-up version of the claims is set forth at the end of this response under the heading "Marked-up Version of the Claims."

B1 Sub DI
1. (Once amended) A preparation in powder form for administration through mucosa, comprising a medicine of high molecular weight and aminoalkylmethacrylate copolymer or polyvinyl acetal diethylaminoacetate. ^(ACE)

Sub DI
8. (Once amended) The preparation of claim 7, wherein the protein is a granulocyte colony-stimulating factor.

9. (Once amended) The preparation of any one of claims 1, 2, 6, 7, or 13-20, which is a preparation for pernasal administration.

Please add new claims 13-20 which follow below.

B3
13. (New) The preparation of claim 1, which comprises 0.1 to 90 w/w% of aminoalkylmethacrylate copolymer or polyvinyl acetal diethylaminoacetate.

Sub DI
14. (New) The preparation of claim 1, which comprises 1 to 50 w/w% of aminoalkylmethacrylate copolymer or polyvinyl acetal diethylaminoacetate.

DI cont.
15. (New) The preparation of claim 1, which improves absorption of the medicine of high molecular weight through mucosa.

16. (New) The preparation of claim 15, wherein the medicine of high molecular weight is selected from the group consisting of calcitonin, insulin, proinsulin, vasopressin, desmopressin, luteinizing hormone, luteinizing hormone-releasing hormone, somatostatin, prolactin, glucagon, gastrin, secretin,

B3
CMT

20. (New) The preparation of claim 1, further comprising an adjuvant.